Switzerland-based Roche has launched the new elecsys anti-müllerian hormone (AMH) blood test, the first fully automated AMH method designed to evaluate a woman’s ovarian reserve.

Healthcare professionals use AMH as an important fertility marker to assess ovarian reserve levels.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Compared to the follicle-stimulating hormone (FSH) and estradiol, the AMH blood test is claimed to be a superior indicator of ovarian reserve and it can be measured during any day of the menstrual cycle.

In addition, the Elecsys AMH blood test produces standardised results for evaluating ovarian reserve as compared with the use of ultrasound, with the result often dependent on the operator or clinic.

"The introduction of our Elecsys AMH test will enable healthcare professionals to incorporate AMH testing into routine clinical practice, while getting more reliable results faster than conventional protocols and manual AMH assays."

Roche Diagnostics chief operating officer Roland Diggelmann said: "The introduction of our Elecsys AMH test will enable healthcare professionals to incorporate AMH testing into routine clinical practice while getting more reliable results faster than conventional protocols and manual AMH assays.

"It is an important example of our focus on improving diagnostics in the area of women’s health."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The test will be available in all markets accepting the CE Mark in Europe, Latin America, Middle East, Africa and Asia, while it is currently not available in the US and Japan.

In future, the company intends to use the Elecsys AMH test in combination with the new human recombinant follicle-stimulating hormone (human rFSH) treatment, which is currently in Phase III development at Ferring Pharmaceuticals.

The combination is expected to provide an improved option for couples seeking to conceive through in vitro fertilisation.

Around 80 million people across the globe are facing fertility issues, according to the World Health Organization (WHO).

The company said that the combination will make possible individualised dosing of human rFSH based on a woman’s specific AMH level.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact